FIELD: medicine. SUBSTANCE: method involves administering the antibody in therapeutic dose specifically binding avβ6. Hybridoma is also developed as producer of the mentioned antibody. EFFECT: enhanced effectiveness in inhibiting integrine receptor avβ6,. 9 cl, 3 dwg
Authors
Dates
2004-01-20—Published
1998-08-07—Filed